MARKET

DWTX

DWTX

Dogwood Therapeutics
NASDAQ
4.160
+0.020
+0.48%
After Hours: 4.160 0 0.00% 19:55 12/31 EST
OPEN
4.090
PREV CLOSE
4.140
HIGH
4.330
LOW
4.000
VOLUME
11.35K
TURNOVER
--
52 WEEK HIGH
29.28
52 WEEK LOW
1.870
MARKET CAP
123.67M
P/E (TTM)
-0.1669
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DWTX last week (1222-1226)?
Weekly Report · 12/29/2025 09:24
What's Driving the Market Sentiment Around Dogwood Therapeutics Inc?
Benzinga · 12/24/2025 16:00
Halneuron Shows Pain Relief Separation In Interim Phase 2b Trial
NASDAQ · 12/23/2025 11:00
CK Life Sciences Subsidiary Dogwood Therapeutics Reports Positive Interim Results in Pain Drug Trial
Reuters · 12/22/2025 23:51
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 12/22/2025 17:05
Dogwood announces interim Phase 2b trial results on Halneuron
TipRanks · 12/22/2025 15:20
Dogwood Therapeutics Reports Interim Results For Halneuron In Chemotherapy-Induced Neuropathic Pain Study; Expects Top-Line Results Availability In Q3 2026
Benzinga · 12/22/2025 15:17
Dogwood Therapeutics Reports Positive Interim Phase 2b Results for Halneuron in Chemotherapy-Induced Neuropathic Pain
Reuters · 12/22/2025 15:15
More
About DWTX
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).

Webull offers Dogwood Therapeutics Inc stock information, including NASDAQ: DWTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DWTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DWTX stock methods without spending real money on the virtual paper trading platform.